D1560C00001: A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer who have Progressed Following Prior
This is a clinical trial of investigational drug AZD9291 which will be administered orally.
IRB Protocol #
BREANNA PRITCHARD at (720)848-0498 or BREANNA.PRITCHARD@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period will determine eligibility. You will first go through several tests and procedures to make sure that you are eligible to take part in the study. If the results of the screening tests confirm that you can take part in the study you will be asked to return to the clinic within 28 days to participate in the study. You may continue to take the study drug as long as you and your study doctor believe you are receiving benefit and there are no medical problems, which might lead to withdrawal from the study. Once you stop the study drug, there will be a Treatment Stopped Visit as well as a Follow Up visit 28 days after your last dose of study drug. // Eligibility criteria include but are not limited to 18 years or older with Advanced Non-Small Cell Lung Cancer.Eligibility criteria include but are not limited to 18 years or older with Advanced Non-Small Cell Lung Cancer.